Enrollment of two additional subjects completed in the domestic Phase III trial (WAKABA) using the new drug ume daptanib pegol, bringing total to three. Trial conducted at 16 sites with patient enrollment proceeding as planned. No impact on the FY2027 full-year results.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"Lifemix Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4591-20260902-01.pdf","jir_short_summary":"Enrollment of two additional subjects completed in the domestic Phase III trial (WAKABA) using the new drug ume daptanib pegol, bringing total to three. Trial conducted at 16 sites with patient enrollment proceeding as planned. No impact on the FY2027 full-year results.","jir_summary":"### Section Heading\nProgress report on the domestic Phase III clinical trial of the osteogenesis imperfecta treatment ume daptanib pegol (WAKABA study). Two additional subject registrations have been completed, bringing the cumulative total to three. The target is 16 registrations, and trial sites were fully prepared as of August 24, 2026. The study is progressing as planned, and enrollment will continue in coordination with the trial institutions. No financial impact is expected for the FY2027 full-year results.\n\n### Section 2 Heading\nUmedaptanib pegol is an aptamer that inhibits FGF2 and is expected to directly influence the pathogenesis of osteogenesis imperfecta. It has been designated as an orphan drug, and further trial progress may affect the development roadmap. Investors should monitor the timing of safety and efficacy data acquisition at trial completion and the accompanying funding plans.","jir_financial_highlights":"Cumulative subject enrollment: 3 cases (new registrations 2 cases)","jir_category":"","jir_hashtags":"#\u30ea\u30dc\u30df\u30c3\u30af, Clinical trial progress, not share buyback, \u6cbb\u9a13, WAKABA\u8a66\u9a13","jir_key_figures":"Cumulative subject registrations: 3 cases\nNew registrations: 2 cases\nDate of completion of clinical trial framework setup: 2026-08-24","jir_meta_title":"\u3010Lifemix\u3011Osteogenesis Imperfecta Treatment Domestic Phase III Progress \u2013 3 Subject Enrollments Achieved","jir_meta_description":"Lifemix reports two more enrollments in the domestic Phase III trial (WAKABA) for osteogenesis imperfecta treatment ume daptanib pegol, bringing total to three. 16-site trial system established. No financial impact for FY2027.","jir_og_title":"\u3010Lifemix\u3011 Domestic Phase III WAKABA trial enrollments reach 3","jir_og_description":"Lifemix's Phase III trial for the osteogenesis imperfecta treatment enrolls two additional subjects, totaling three. Trial progressing as planned; no financial impact in the 2027 fiscal year.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-110013","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n